Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 18.3% in October

Carisma Therapeutics, Inc. (NASDAQ:CARM) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 857,500 shares, a decrease of 18.3% from the October 15th total of 1,050,000 shares. Based on an average daily volume of 146,200 shares, the days-to-cover ratio is currently 5.9 days. Approximately 4.0% of the company’s stock are sold short.

Carisma Therapeutics Stock Performance

CARM stock traded down $0.06 during mid-day trading on Friday, reaching $0.88. 238,783 shares of the stock traded hands, compared to its average volume of 341,220. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a 52 week low of $0.80 and a 52 week high of $3.16. The business has a 50-day moving average of $0.98 and a two-hundred day moving average of $1.13. The firm has a market capitalization of $36.87 million, a PE ratio of -0.57 and a beta of 1.49.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The company had revenue of $3.39 million during the quarter. As a group, equities analysts predict that Carisma Therapeutics will post -1.33 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Institutional Investors Weigh In On Carisma Therapeutics

Hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. Wexford Capital LP lifted its stake in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Carisma Therapeutics in the second quarter valued at about $40,000. Finally, Vanguard Group Inc. lifted its stake in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after buying an additional 11,200 shares during the period. 44.27% of the stock is currently owned by institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.